SOPHiA GENETICS SA (NASDAQ:SOPH – Get Free Report) insider Zhenyu Xu sold 4,000 shares of the stock in a transaction dated Monday, July 13th. The shares were sold at an average price of $5.70, for a total transaction of $22,800.00. Following the completion of the transaction, the insider directly owned 610,887 shares in the company, valued at $3,482,055.90. The trade was a 0.65% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Zhenyu Xu also recently made the following trade(s):
- On Monday, July 6th, Zhenyu Xu sold 7,393 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.17, for a total transaction of $38,221.81.
- On Monday, April 20th, Zhenyu Xu sold 608 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.21, for a total transaction of $3,167.68.
SOPHiA GENETICS Stock Up 1.0%
Shares of SOPH opened at $5.83 on Friday. The firm has a market cap of $489.08 million, a P/E ratio of -11.21 and a beta of 0.96. The company has a debt-to-equity ratio of 1.05, a quick ratio of 1.90 and a current ratio of 2.06. SOPHiA GENETICS SA has a 52 week low of $2.92 and a 52 week high of $6.30. The firm’s 50-day simple moving average is $5.22 and its 200 day simple moving average is $5.01.
Analyst Upgrades and Downgrades
Several research firms recently issued reports on SOPH. BTIG Research restated a “buy” rating and issued a $8.00 price target on shares of SOPHiA GENETICS in a research note on Monday, June 15th. Weiss Ratings reissued a “sell (d-)” rating on shares of SOPHiA GENETICS in a report on Tuesday, April 21st. Two investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $7.50.
Institutional Inflows and Outflows
Several hedge funds have recently made changes to their positions in SOPH. First Dallas Securities Inc. acquired a new stake in shares of SOPHiA GENETICS in the first quarter valued at approximately $50,000. Squarepoint Ops LLC acquired a new stake in SOPHiA GENETICS during the third quarter worth approximately $49,000. Perkins Capital Management Inc. bought a new position in SOPHiA GENETICS during the 4th quarter worth $49,000. Quadrature Capital Ltd bought a new position in SOPHiA GENETICS during the 4th quarter worth $54,000. Finally, XTX Topco Ltd acquired a new position in SOPHiA GENETICS in the 4th quarter valued at $55,000. 31.59% of the stock is owned by institutional investors.
SOPHiA GENETICS Company Profile
SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.
The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.
Read More
- Five stocks we like better than SOPHiA GENETICS
- Why Abbott Laboratories Stock Is Suddenly Winning Back Wall Street
- Revving Up Returns: Big Banks Race Through the Rate Plateau
- Why Uber’s Biggest Deal Yet Could Unlock Its Next Growth Phase
- Why Microsoft Is Playing a Different AI Game Than Big Tech—and Cash Flow Is the Test
Receive News & Ratings for SOPHiA GENETICS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SOPHiA GENETICS and related companies with MarketBeat.com's FREE daily email newsletter.
